Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

Imetelstat: A new addition to the Therapeutic Landscape of Lower-Risk MDS

Yasmin Abaza, Amy E. DeZern

Blood blood.2024025702.

https://doi.org/10.1182/blood.2024025702

Published: 2024

Includes: Supplemental data

Journal Articles

Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Blood (2024) 144 (Supplement 1): 2134.1.

https://doi.org/10.1182/blood-2024-207952

Published: 2024

Journal Articles

A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears

Palak Dave, Jordan Rai, Ling Zhang, Mohammad Omar Hussaini, Mary Ellen Walker, Nancy Gillis, Mikkael A. Sekeres, Amy E. DeZern, Eric Padron, Rami S. Komrokji, Issam El Naqa

Blood (2024) 144 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2024-207735

Published: 2024

Journal Articles

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Blood (2024) 144 (Supplement 1): 1332.

https://doi.org/10.1182/blood-2024-194024

Published: 2024

Journal Articles

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Zhuoer Xie, Zena Komrokji, Michael Otterstatter, Ling Zhang, Lynn C. Moscinski, Najla H. Al Ali, David Sallman, Jeffrey E Lancet, Amy E. DeZern, Mikkael A. Sekeres, Rami S. Komrokji, Nancy Gillis, Eric Padron

Blood (2024) 144 (Supplement 1): 354.

https://doi.org/10.1182/blood-2024-203837

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Clonal Dissection of MDS and Secondary AML Resolves Shared Splicing Neoantigens and Mechanistic Underpinnings of Hypomethylating Agent Therapeutic Response

Xuan Zhang, Guangyuan Li, Anna Oliverio, Jennifer VanOudenhove, Amy E. DeZern, Gabriel Ghiaur, Stephanie Halene, H. Leighton Grimes, Nathan Salomonis

Blood (2024) 144 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2024-211099

Published: 2024

Journal Articles

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2024) 144 (Supplement 1): 2071.

https://doi.org/10.1182/blood-2024-208021

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Wenyi Fan, Sara M. Tinsley-Vance, Amy E. DeZern, Hetty E. Carraway, Marlise R. Luskin, Gail J. Roboz, Onyee Chan, Aaron T. Gerds, Andrew T. Kuykendall, David P. Steensma, Maria Balasis, Jeffrey E Lancet, Qianxing Mo, Mikkael A. Sekeres, David Sallman, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 6750.

https://doi.org/10.1182/blood-2024-211137

Published: 2024

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Blood (2024) 144 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2024-201613

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Mikkael A. Sekeres, Hanny Al-Samkari, Hetty E. Carraway, Amy E. DeZern, Moshe Mittelman, Meredith Little, Vanessa Beynon, Xiaoshu Dai, Sal Sommakia, Jenny M. Despotovic, Parija Patel, Melissa Dibacco, Bruno Fattizzo, Eytan M. Stein, David Sallman, Austin G. Kulasekararaj, Uwe Platzbecker, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 6708.

https://doi.org/10.1182/blood-2024-203073

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

A way to “mimic” the pathophysiology of acquired SAA

Amy E. DeZern

Blood (2024) 143 (14): 1318–1320.

https://doi.org/10.1182/blood.2024024037

Published: 2024

NARROW

Imetelstat: A new addition to the Therapeutic Landscape of Lower-Risk MDS

Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Clonal Dissection of MDS and Secondary AML Resolves Shared Splicing Neoantigens and Mechanistic Underpinnings of Hypomethylating Agent Therapeutic Response

Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Reduction in MPN-Total Symptom Score (TSS) Is Associated with Overall Survival (OS) in Chronic Myelomonocytic Leukemia (CMML)

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

A way to “mimic” the pathophysiology of acquired SAA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only